Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

1. Emtricitabine + tenofovir disoproxil (Truvada and other brands) for prevention of HIV infection in adolescents

Emtricitabine + tenofovir disoproxil (Truvada and other brands) for prevention of HIV infection in adolescents Prescrire IN ENGLISH - Spotlight ''Emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents'', 1 July 2019 {1} {1} {1} | | > > > Emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight In the July-August issue of Prescrire International: emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents FREE DOWNLOAD Based on extrapolation of the data obtained in adults, the emtricitabine + tenofovir disoproxil combination (Truvada° or other brands) appears worth offering to adolescents whose sex practices place them at particularly

2019 Prescrire

2. Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services

Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services , , , , Questions (...) What strategies have been successful at linking people with undiagnosed HIV infection to HIV testing, care, and prevention services? Key take-home messages A variety of strategies have shown promise for identifying individuals with undiagnosed HIV and engaging them with HIV testing using clinical, community-based, network-based, and self-directed approaches. Various service delivery models for implementing rapid initiation of antiretroviral treatment have demonstrated benefits for linking the newly

2019 Ontario HIV Treatment Network

3. Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection

Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection Document ID CHQ-GDL-01243 Version no. 3.1 Approval date 28/05/2019 Executive sponsor Executive Director Medical Services Effective date 28/05/2019 Author/custodian Infectious Diseases Physician - Infection Management and Prevention services Review date 28/05/2021 Supercedes 3.0 Applicable to All Children’s Health Queensland (...) staff Authorisation Executive Director Clinical Services (QCH) Purpose This guideline provides best practice recommendations for obstetricians, paediatricians, neonatologists and Human Immunodeficient Virus (HIV) physicians regarding management of infants born to women with HIV infection. Scope This Guideline provides information for all Children’s Health Queensland (CHQ) employees (permanent, temporary and casual) and all organisations and individuals acting as its agents (including Visiting

2019 Queensland Health

4. Classification versus Prediction of Mortality Risk using the SIRS and qSOFA Scores in Patients with Infection Transported by Paramedics

Classification versus Prediction of Mortality Risk using the SIRS and qSOFA Scores in Patients with Infection Transported by Paramedics Objective: Identifying patients with sepsis in the prehospital setting is an important opportunity to increase timely care. When assessing clinical tools designed for paramedic sepsis identification, predicted risk may provide more useful information to support decision-making, compared to traditional estimates of classification accuracy (i.e., sensitivity (...) and specificity). We sought to contrast classification accuracy versus predicted risk of a modified version of the Systemic Inflammatory Response Syndrome score (i.e., excluding white blood cell measure which is often unavailable to paramedics; mSIRS) and quick Sepsis Related Organ Failure Assessment (qSOFA) for determining mortality risk among patients with infection transported by paramedics. Methods: A one-year cohort of patients with infections transported to the Emergency Department (ED) by paramedics

2019 EvidenceUpdates

5. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU

Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019) - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular (...) Practice Resources Coding and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019) Published 2019 [pdf] [pdf] Panel Members Jennifer Anger, MD, MPH; Una Lee, MD; A. Lenore Ackerman, MD, PhD; Roger Chou, MD; Bilal Chughtai, MD; J. Quentin Clemens, MD; Duane Hickling, MD, MSCI; Anil Kapoor, MD; Kimberly S. Kenton, MD, MS; Melissa R. Kaufman

2019 Canadian Urological Association

6. Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018) (Full text)

Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018) Device-related infection (DRI) is a severe complication to cardiac implantable electronic devices (CIED) therapy. Device-related infection incidence and its risk factors differ between previous studies. We aimed to define the long-term incidence and incidence rates of DRI for different types of CIEDs in the complete Danish device-cohort and identify patient-, operation (...) - and device-related risk factors for DRI.From the Danish Pacemaker (PM) and implantable cardioverter-defibrillator (ICD) Register, we included consecutive Danish patients undergoing CIED implantation or reoperation from January 1982 to April 2018, resulting in 97 750 patients, 128 045 operations and follow-up of in total 566 275 device years (DY). We identified 1827 DRI causing device removals. Device-related infection incidence during device lifetime was 1.19% (1.12-1.26) for PM, 1.91% (1.71-2.13

2019 EvidenceUpdates PubMed

7. Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and decreased transmission risk in persons with CD4 cell counts less than 500/mm3.To update (...) there was no direct evidence on the clinical benefits and harms of screening for HIV infections vs no screening, or the yield of repeat or alternative screening strategies. New evidence extends effectiveness of ART to asymptomatic individuals with CD4 cell counts greater than 500/mm3 and shows sustained reduction in risk of HIV transmission at longer-term follow-up, although certain ART regimens may be associated with increased risk of long-term harms.

2019 JAMA

8. Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (PubMed)

Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Prenatal screening for HIV can inform use of interventions to reduce the risk of mother-to-child transmission. The US Preventive Services Task Force (USPSTF) previously found strong evidence that prenatal HIV screening reduced risk of mother-to-child transmission. The previous evidence review was conducted in 2012.To update the 2012 review on prenatal HIV (...) regimens during pregnancy was associated with increased risk of harms that may be mitigated by selection of ART regimen. The 2012 review found that avoidance of breastfeeding and cesarean delivery in women with viremia also reduced risk of transmission and that prenatal screening accurately diagnosed HIV infection.

2019 JAMA

9. Neonatal Herpes Simplex Virus Infection Among Medicaid-Enrolled Children: 2009-2015

Neonatal Herpes Simplex Virus Infection Among Medicaid-Enrolled Children: 2009-2015 To examine the incidence, mortality, and health care use related to neonatal herpes simplex virus (HSV) infection.A retrospective longitudinal cohort study using a multistate Medicaid claims database. We identified neonates hospitalized with HSV infection from 2009 to 2015 by using discharge diagnosis codes and managed them for 6 months after discharge. Incidence rates were corrected for the imperfect (...) sensitivity and specificity of thediagnosis codes for identifying HSV infection.Of 2 107 124 births from 2009 to 2015, 900 neonates were identified with HSV infection, with a corrected incidence rate of 4.5 (95% confidence interval [CI]: 4.2-4.8) per 10 000 births. The yearly disease incidence increased by 56%, from 3.4 (95% CI: 2.8-4.2) per 10 000 births (or 1 in 2941 births) in 2009 to 5.3 (95% CI: 4.6-6.1) per 10 000 births (or 1 in 1886 births) in 2015 (P < .001). Of the 900 neonates with HSV

2019 EvidenceUpdates

10. Chiefs’ inquiry corner: monoclonal antibodies and clostridium difficile infection, outcomes after in-hospital cardiac arrest v out-of-hospital, dermatomyositis and malignancy, malignancy work up in unprovoked VTE.

Chiefs’ inquiry corner: monoclonal antibodies and clostridium difficile infection, outcomes after in-hospital cardiac arrest v out-of-hospital, dermatomyositis and malignancy, malignancy work up in unprovoked VTE. Chiefs’ Inquiry Corner – Clinical Correlations Search Chiefs’ Inquiry Corner June 10, 2019 3 min read Clostridium difficile (C diff) is the most common pathogen implicated in infectious diarrhea among hospitalized patients. Several antimicrobials, chief among them an oral formulation (...) of vancomycin, are utilized to combat and prevent infection in appropriate patients. Monoclonal antibodies specific to cdiff’s binary toxins A and B have also been developed and can be effective in reducing recurrent infection. The MODIFY trials (2017) randomized patients being treated with standard antibiotics for c diff infection to additional infusion of either monoclonal antibody to toxin A (actoxumab), toxin B (bezlotoxumab), or both, compared to placebo controls. (The group receiving actoxumab alone

2019 Clinical Correlations

11. Pegfilgrastim (Fulphila) - decreasing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs.

Pegfilgrastim (Fulphila) - decreasing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs. Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information

2019 Health Canada - Drug and Health Product Register

12. Human Immunodeficiency Virus (HIV) Infection: Screening

Human Immunodeficiency Virus (HIV) Infection: Screening Final Update Summary: Human Immunodeficiency Virus (HIV) Infection: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Summary YouTube embedded video: https://www.youtube-nocookie.com/embed/guahk43RkV4 Human Immunodeficiency Virus (HIV) Infection: Screening Release Date: June 2019 Recommendation Summary Population Recommendation (...) Grade Adolescents and adults aged 15 to 65 years The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. Pregnant persons The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown. To read the recommendation statement in JAMA , select

2019 U.S. Preventive Services Task Force

13. Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis

Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis Final Update Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Summary YouTube embedded video: https://www.youtube-nocookie.com/embed/guahk43RkV4 Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure (...) therapy. ( ) Related Information for Consumers Related Information for Health Professionals Supporting Documents ( ) ( ) Clinical Summary Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice. This summary is intended for use by primary care clinicians. ( ) Current as of: June 2019 Internet Citation: Final Update Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis . U.S. Preventive

2019 U.S. Preventive Services Task Force

14. Latent TB infection (LTBI): testing and treatment

Latent TB infection (LTBI): testing and treatment Latent TB infection testing and treatment programme Technical guidance and specification Latent TB infection testing and treatment programme: technical guidance and specification 2 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery (...) PHE publications PHE supports the UN gateway number: GW-404 Sustainable Development Goals Latent TB infection testing and treatment programme: technical guidance and specification 3 Contents About Public Health England 2 1. Background 4 1.1 Programme monitoring 4 1.2 Eligibility 4 1.3 Testing 5 1.4 Treatment 5 2. Aim of document 6 3. Data flow process 7 3.1 Testing data 7 3.2 Community/secondary care/treatment data collection 8 3.3 LTBI data excel template 8 3.4 Laboratory data 8 4. Data extract

2019 Public Health England

15. Preventing and managing bacterial wound infections in prison

Preventing and managing bacterial wound infections in prison Management and prevention of bacterial wound infections in prescribed places of detention Guidelines for healthcare, custodial staff and responding health protection services Management and prevention of bacterial wound infections in prescribed places of detention 2 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world (...) OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Published June 2019 PHE publications PHE supports the UN gateway number: GW-476 Sustainable Development Goals Management and prevention of bacterial wound infections in prescribed places of detention 3 Contents Glossary 4 Introduction 5 Available resources 5 How to use this document 6 Recommendations for healthcare staff 8 Case identification and assessment

2019 Public Health England

16. Curos for preventing infections when using needleless connectors

Curos for preventing infections when using needleless connectors Curos for pre Curos for prev venting infections when enting infections when using needleless connectors using needleless connectors Medical technologies guidance Published: 9 May 2019 www.nice.org.uk/guidance/mtg44 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived (...) . Curos for preventing infections when using needleless connectors (MTG44) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents Contents 1 Recommendations 4 2 The technology 6 3 Evidence 7 Clinical evidence 7 Cost evidence 8 4 Committee discussion 10 Clinical-effectiveness overview 10 NHS considerations overview 11 Cost modelling overview 12 Main cost drivers 12 Further research 12 5 Committee members

2019 National Institute for Health and Clinical Excellence - Medical technologies

17. The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)

The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, +31 January 2019] Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment C-REACTIVE PROTEIN POINT-OF-CARE (...) TESTING (CRP POCT) TO GUIDE ANTIBIOTIC PRESCRIBING IN PRIMARY CARE SETTINGS FOR ACUTE RESPIRATORY TRACT INFECTIONS (RTIS) Project ID: OTCA012 C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V1.0 26/10/2018 First draft. V1.1 03/12/2018 Input from co-author has been processed. V1.2 03/12/2018 Input from dedicated reviewers has been

2019 EUnetHTA

18. A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection

A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection | The Ontario HIV Treatment Network The Ontario HIV Treatment Network A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection (...) , , , , , , , , , , Question At what intervals do high-income jurisdictions encourage population groups at high risk of HIV infection to come forward for routine testing? Key take-home messages Most guidelines recommend at least annual HIV testing of population groups at high risk of HIV infection. These include: men who have sex with men, transgender women and men, people who use injection drugs, African, Caribbean and Black communities, indigenous people, and women at risk. Some guidelines recommend more frequent

2019 Ontario HIV Treatment Network

19. Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection

Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection SHTG Evidence Synthesis | 1 Evidence Synthesis Number 01 March 2019 Pre-emptive antifungal strategies incorporating galactomannan (GM) testing and/or polymerase chain reaction (PCR) assays compared with empirical antifungal strategies for invasive Aspergillus infection in patients with haematological malignancies What were we asked to look at? The Scottish Antimicrobial Prescribing Group (SAPG) asked us (...) to look at pre-emptive strategies incorporating galactomannan (GM) testing and/or polymerase chain reaction (PCR) assays compared with empirical antifungal treatment strategies for invasive Aspergillus infection in patients with haematological malignancies. Why is this important? Patients receiving treatments for haematological malignancies often experience severe and prolonged neutropenia which puts them at risk of life-threatening invasive fungal infections including Aspergillus infection. Since

2019 SHTG Advice Statements

20. Beta-D-glucan (BDG) tests for invasive Candida infection

Beta-D-glucan (BDG) tests for invasive Candida infection SHTG Advice Statement | 1 Advice Statement 02-19 January 2019 Advice Statement Clinical and cost effectiveness of diagnostic strategies incorporating Beta-D-glucan (BDG) tests to reduce unnecessary use of empirical antifungal therapies for invasive Candida infection in the critical care setting Advice for NHSScotland Overuse of empirical antifungal therapies in the critical care setting is a significant problem which exposes patients (...) is not fully offset by the savings realised from the reduction in antifungal use; SHTG Advice Statement | 2 ? The strategy is associated with a minimal incremental cost or is potentially cost- saving, in settings with higher testing throughputs (maximising test kit utilisation) and where there is low infection prevalence and high empirical use, and where micafungin or amphotericin B are the most commonly used agents; ? In units where use of empirical therapy is less common costs may be significantly

2019 SHTG Advice Statements